Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Inflammation
Published in: Inflammation 1/2018

01-02-2018 | ORIGINAL ARTICLE

A Novel Role of a Chemotherapeutic Agent in a Rat Model of Endotoxemia: Modulation of the STAT-3 Signaling Pathway

Authors: Omnia S. Zaki, Marwa M. Safar, Afaf A. Ain-Shoka, Laila A. Rashed

Published in: Inflammation | Issue 1/2018

Login to get access

Abstract

Sepsis caused by lipopolysaccharide (LPS) is a life-threatening disease accompanied by multiple organ failure. This study investigated the curative effects of imatinib (IMA) against hepatic, renal, and pulmonary responses caused by a single administration of LPS (10 mg/kg, i.p.) in rats. Treatment with IMA (15 mg/kg, i.p.) 30 min after LPS antagonized the LPS-induced boost of liver enzymes (ALT, AST), kidney functions (BUN, sCr) as well as the elevated pulmonary vascular permeability and edema. IMA declined tissue contents of NF-κB, STAT-3, P38-MAPK, TNF-α, IL-1β, and iNOS. It also amplified the anti-inflammatory cytokine IL-10 as well as the Bcl-2/Bax ratio, a cardinal indicator of the anti-apoptotic effect. Meanwhile, the rats exhibited marked reduction of the broncho-alveolar lavage fluid (BALF) contents of TNF-α, IL-1β, IFN-γ, and neutrophil count; however, they revealed prominent augmentation of the BALF content IL-10. In conclusion, these findings suggest that IMA is endowed with anti-inflammatory, anti-oxidant, and anti-apoptotic properties and hence may provide a novel agent for the management of sepsis.
Literature
1.
2.
Stehr, S.N., and K. Reinhart. 2013. Sepsis as a global health problem—why we need a global sepsis alliance. Shock 39: 3–4.CrossRefPubMed
3.
Lombardo, E., T. van der Poll, O. DelaRosa, and W. Dalemans. 2015. Mesenchymal stem cells as a therapeutic tool to treat sepsis. World Journal Stem Cells 7: 368–379.CrossRef
4.
Su, G.L. 2002. Lipopolysaccharides in liver injury: molecular mechanisms of Kupffer cell activation. American Journal of Physiology. Gastrointestinal and Liver Physiology 283: G256–G265.CrossRefPubMed
5.
Glaucer, M.P., G. Zanetti, J.D. Baumgartner, and J. Cohen. 1991. Septic shock: pathogenesis. Lancet 338: 732–739.CrossRef
6.
Ghosh, S., R.D. Latimer, B.M. Gray, R.J. Harwood, and A. Oduro. 1993. Endotoxin-induced organ injury. Critical Care Medicine 21: S19–S24.CrossRefPubMed
7.
Takahashi, K., H. Mizukami, K. Kamata, W. Inaba, N. Kato, C. Hibi, and S. Yagihashi. 2012. Amelioration of acute kidney injury in lipopolysaccharide-induced systemic inflammatory response syndrome by an aldose reductase inhibitor, fidarestat. PloS One 7: e30134.CrossRefPubMedPubMedCentral
8.
Ma, L., X.Y. Wu, L.H. Zhang, W.M. Chen, A. Uchiyama, T. Mashimo, and Y. Fujino. 2013. Propofol exerts anti-inflammatory effects in rats with lipopolysaccharide-induced acute lung injury by inhibition of CD14 and TLR4 expression. Brazilian Journal of Medical and Biological Research 46: 299–305.CrossRefPubMedPubMedCentral
9.
Shimazu, R., S. Akashi, H. Ogata, Y. Nagai, K. Fukudome, K. Miyake, and M. Kimoto. 1999. MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4. The Journal of Experimental Medicine 189: 1777–1782.CrossRefPubMedPubMedCentral
10.
Wiersinga, W.J., S.J. Leopold, D.R. Cranendonk, and T. van der Poll. 2014. Host innate immune responses to sepsis. Virulence 5: 36–44.CrossRefPubMed
11.
Abreu, M.T., E.T. Arnold, L.S. Thomas, R. Gonsky, Y. Zhou, B. Hu, and M. Arditi. 2002. TLR4 and MD-2 expression is regulated by immune-mediated signals in human intestinal epithelial cells. The Journal of Biological Chemistry 277: 20431–20437.CrossRefPubMed
12.
Manley, P.W., N. Stiefl, S.W. Cowan-Jacob, S. Kaufman, J. Mestan, M. Wartmann, M. Wiesmann, R. Woodman, and N. Gallagher. 2010. Structural resemblances and comparisons of the relative pharmacological properties of imatinib and nilotinib. Bioorganic & Medicinal Chemistry 18: 6977–6986.CrossRef
13.
Rubin, B.P., M.C. Heinrich, and C.L. Corless. 2007. Gastrointestinal stromal tumour. Lancet 369: 1731–1741.CrossRefPubMed
14.
Day, E., B. Waters, K. Spiegel, T. Alnadaf, P.W. Manley, E. Buchdunger, C. Walker, and G. Jarai. 2008. Inhibition of collagen-induced discoidin domain receptor 1 and 2 activation by imatinib, nilotinib and dasatinib. European Journal of Pharmacology 599: 44–53.CrossRefPubMed
15.
Huang, P., X.S. Zhao, M. Fields, R.M. Ransohoff, and L. Zhou. 2009. Imatinib attenuates skeletal muscle dystrophy in mdx mice. The FASEB Journal 23: 2539–2548.CrossRefPubMedPubMedCentral
16.
Wolf, A.M., D. Wolf, H. Rumpold, S. Ludwiczek, B. Enrich, G. Gastl, G. Weiss, and H. Tilg. 2005. The kinase inhibitor imatinib mesylate inhibits TNF-{alpha} production in vitro and prevents TNF-dependent acute hepatic inflammation. Proceedings of the National Academy of Sciences of the United States of America 102: 13622–13627.CrossRefPubMedPubMedCentral
17.
Stephens, R.S., L. Johnston, L. Servinsky, B.S. Kim, and M. Damarla. 2015. The tyrosine kinase inhibitor imatinib prevents lung injury and death after intravenous LPS in mice. Physiological Reports 3: e12589.CrossRefPubMedPubMedCentral
18.
Aman, J., J. van Bezu, A. Damanafshan, S. Huveneers, E.C. Eringa, S.M. Vogel, A.B. Groeneveld, A. Vonk Noordegraaf, V.W. van Hinsbergh, and G.P. van Nieuw Amerongen. 2012. Effective treatment of edema and endothelial barrier dysfunction with imatinib. Circulation 126: 2728–2738.CrossRefPubMed
19.
Letsiou, E., A.N. Rizzo, S. Sammani, P. Naureckas, J.R. Jacobson, J.G. Garcia, and S.M. Dudek. 2015. Differential and opposing effects of imatinib on LPS- and ventilator-induced lung injury. American Journal of Physiology. Lung Cellular and Molecular Physiology 308: L259–L269.CrossRefPubMed
20.
Wang, S., M.C. Wilkes, E.B. Leof, and R. Hirschberg. 2005. Imatinib mesylate blocks a non-Smad TGF-beta pathway and reduces renal fibrogenesis in vivo. The FASEB Journal 19: 1–11.CrossRefPubMed
21.
Yagi, H., A. Soto-Gutierrez, N. Navarro-Alvarez, Y. Nahmias, Y. Goldwasser, Y. Kitagawa, A.W. Tilles, R.G. Tompkins, B. Parekkadan, and M.L. Yarmush. 2010. Reactive bone marrow stromal cells attenuate systemic inflammation via sTNFR1. Molecular Therapy 18: 1857–1864.CrossRefPubMedPubMedCentral
22.
Rossi, F., Y. Yozgat, E. de Stanchina, D. Veach, B. Clarkson, K. Manova, F.G. Giancotti, C.R. Antonescu, and P. Besmer. 2010. Imatinib upregulates compensatory integrin signaling in a mouse model of gastrointestinal stromal tumor and is more effective when combined with dasatinib. Molecular Cancer Research 8: 1271–1283.CrossRefPubMedPubMedCentral
23.
Inami, M., K. Inokuchi, H. Yamaguchi, K. Nakayama, A. Watanabe, N. Uchida, S. Tanosaki, and K. Dan. 2006. Oral administration of imatinib to P230 BCR/ABL-expressing transgenic mice changes clones with high BCR/ABL complementary DNA expression into those with low expression. International Journal of Hematology 84: 346–353.CrossRefPubMed
24.
Freireich, E.J., E.A. Gehan, D.P. Rall, L.H. Schmidt, and H.E. Skipper. 1966. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemotherapy Reports 50: 219–244.PubMed
25.
Cocchetto, D.M., and T.D. Bjornsson. 1983. Methods for vascular access and collection of body fluids from the laboratory rat. Journal of Pharmaceutical Sciences 72: 465–492.CrossRefPubMed
26.
Mei, S.H., S.D. McCarter, Y. Deng, C.H. Parker, W.C. Liles, and D.J. Stewart. 2007. Prevention of LPS-induced acute lung injury in mice by mesenchymal stem cells overexpressing angiopoietin 1. PLoS Medicine 4: e269.CrossRefPubMedPubMedCentral
27.
Lam, C.F., Y.C. Liu, J.K. Hsu, P.A. Yeh, T.Y. Su, C.C. Huang, M.W. Lin, P.C. Wu, P.J. Chang, and Y.C. Tsai. 2008. Autologous transplantation of endothelial progenitor cells attenuates acute lung injury in rabbits. Anesthesiology 108: 392–401.CrossRefPubMed
28.
29.
Vilcek, J., and T.H. Lee. 1991. Tumor necrosis factor. New insights into the molecular mechanisms of its multiple actions. The Journal of Biological Chemistry 266: 7313–7316.PubMed
30.
Eskdale, J., D. Kube, H. Tesch, and G. Gallagher. 1997. Mapping of the human IL10 gene and further characterization of the 5′ flanking sequence. Immunogenetics 46: 120–128.CrossRefPubMed
31.
Thiel, D.J., M.H. le Du, R.L. Walter, A. D'Arcy, C. Chene, M. Fountoulakis, G. Garotta, F.K. Winkler, and S.E. Ealick. 2000. Observation of an unexpected third receptor molecule in the crystal structure of human interferon-gamma receptor complex. Structure 8: 927–936.CrossRefPubMed
32.
Livak, K.J., and T.D. Schmittgen. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2(−delta delta C(T)) method. Methods 25: 402–408.CrossRefPubMed
33.
Bancroft J.D., and A. Stevens. Turner DR. 1996. Theory and practice of histological techniques. In: New York, Churchill, Livingstone. Vol.4th Ed.
34.
Sener, G., H. Toklu, C. Kapucu, F. Ercan, G. Erkanli, A. Kacmaz, M. Tilki, and B.C. Yegen. 2005. Melatonin protects against oxidative organ injury in a rat model of sepsis. Surgery Today 35: 52–59.CrossRefPubMed
35.
Graciano, M.L., and K.D. Mitchell. 2012. Imatinib ameliorates renal morphological changes in Cyp1a1-Ren2 transgenic rats with inducible ANG II-dependent malignant hypertension. American Journal of Physiology. Renal Physiology 302: F60–F69.CrossRefPubMed
36.
An, J., J. Du, N. Wei, T. Guan, A.K. Camara, and Y. Shi. 2012. Differential sensitivity to LPS-induced myocardial dysfunction in the isolated brown Norway and Dahl S rat hearts: roles of mitochondrial function, NF-kappaB activation, and TNF-alpha production. Shock 37: 325–332.CrossRefPubMedPubMedCentral
37.
Geng, Y., B. Zhang, and M. Lotz. 1993. Protein tyrosine kinase activation is required for lipopolysaccharide induction of cytokines in human blood monocytes. Journal of Immunology 151: 6692–6700.
38.
Liu, S.H., K. Ma, X.R. Xu, and B. Xu. 2010. A single dose of carbon monoxide intraperitoneal administration protects rat intestine from injury induced by lipopolysaccharide. Cell Stress & Chaperones 15: 717–727.CrossRef
39.
Craig, R., A. Larkin, A.M. Mingo, D.J. Thuerauf, C. Andrews, P.M. McDonough, and C.C. Glembotski. 2000. p38 MAPK and NF-kappa B collaborate to induce interleukin-6 gene expression and release. Evidence for a cytoprotective autocrine signaling pathway in a cardiac myocyte model system. The Journal of Biological Chemistry 275: 23814–23824.CrossRefPubMed
40.
Crespo, E., M. Macias, D. Pozo, G. Escames, M. Martin, F. Vives, J.M. Guerrero, and D. Acuna-Castroviejo. 1999. Melatonin inhibits expression of the inducible NO synthase II in liver and lung and prevents endotoxemia in lipopolysaccharide-induced multiple organ dysfunction syndrome in rats. The FASEB Journal 13: 1537–1546.PubMed
41.
Forman, H.J., and M. Torres. 2001. Redox signaling in macrophages. Molecular Aspects of Medicine 22: 189–216.CrossRefPubMed
42.
Sakon, S., X. Xue, M. Takekawa, T. Sasazuki, T. Okazaki, Y. Kojima, J.H. Piao, H. Yagita, K. Okumura, T. Doi, and H. Nakano. 2003. NF-kappaB inhibits TNF-induced accumulation of ROS that mediate prolonged MAPK activation and necrotic cell death. The EMBO Journal 22: 3898–3909.CrossRefPubMedPubMedCentral
43.
Severgnini, M., S. Takahashi, L.M. Rozo, R.J. Homer, C. Kuhn, J.W. Jhung, G. Perides, M. Steer, P.M. Hassoun, B.L. Fanburg, B.H. Cochran, and A.R. Simon. 2004. Activation of the STAT pathway in acute lung injury. American Journal of Physiology. Lung Cellular and Molecular Physiology 286: L1282–L1292.CrossRefPubMed
44.
Adzemovic, M.V., M. Zeitelhofer, U. Eriksson, T. Olsson, and I. Nilsson. 2013. Imatinib ameliorates neuroinflammation in a rat model of multiple sclerosis by enhancing blood-brain barrier integrity and by modulating the peripheral immune response. PloS One 8: e56586.CrossRefPubMed
45.
Faggiona, R., S. Gatt, M.T. Demetri, R. Delgado, B. Echternacher, P. Gnocchi, H. Heremans, and P. Ghezzi. 1994. Role of xanthine oxidase and reactive oxygen intermediates in LPS- and TNF-induced pulmonary edema. The Journal of Laboratory and Clinical Medicine 123: 394–399.
46.
Chi, G., M. Wei, X. Xie, L.W. Soromou, F. Liu, and S. Zhao. 2013. Suppression of MAPK and NF-kappaB pathways by limonene contributes to attenuation of lipopolysaccharide-induced inflammatory responses in acute lung injury. Inflammation 36: 501–511.CrossRefPubMed
47.
Rhee, C.K., J.W. Kim, C.K. Park, J.S. Kim, J.Y. Kang, S.J. Kim, S.C. Kim, S.S. Kwon, Y.K. Kim, S.H. Park, and S.Y. Lee. 2011. Effect of imatinib on airway smooth muscle thickening in a murine model of chronic asthma. International Archives of Allergy and Immunology 155: 243–251.CrossRefPubMed
48.
Petit-Bertron, A.F., C. Fitting, J.M. Cavaillon, and M. Adib-Conquy. 2003. Adherence influences monocyte responsiveness to interleukin-10. Journal of Leukocyte Biology 73: 145–154.CrossRefPubMed
49.
Ledeboer, A., J.J. Breve, S. Poole, F.J. Tilders, and A.M. Van Dam. 2000. Interleukin-10, interleukin-4, and transforming growth factor-beta differentially regulate lipopolysaccharide-induced production of pro-inflammatory cytokines and nitric oxide in co-cultures of rat astroglial and microglial cells. Glia 30: 134–142.CrossRefPubMed
50.
Zhang, Z., D.L. Qin, J.Y. Wan, Q.X. Zhou, S.H. Xiao, and K. Wu. 2008. Effects of asiaticoside on the balance of inflammatory factors of mouse's acute lung injury induced by LPS. Zhong Yao Cai 31: 547–549.PubMed
51.
Xu, X.L., Q.M. Xie, Y.H. Shen, J.J. Jiang, Y.Y. Chen, H.Y. Yao, and J.Y. Zhou. 2008. Mannose prevents lipopolysaccharide-induced acute lung injury in rats. Inflammation Research 57: 104–110.CrossRefPubMed
52.
Marchant, A., C. Bruyns, P. Vandenabeele, M. Ducarme, C. Gerard, A. Delvaux, D. De Groote, D. Abramowicz, T. Velu, and M. Goldman. 1994. Interleukin-10 controls interferon-gamma and tumor necrosis factor production during experimental endotoxemia. European Journal of Immunology 24: 1167–1171.CrossRefPubMed
53.
Cai, Y., Z. Zou, L. Liu, S. Chen, Y. Chen, Z. Lin, K. Shi, L. Xu, and Y. Chen. 2015. Bone marrow-derived mesenchymal stem cells inhibits hepatocyte apoptosis after acute liver injury. International Journal of Clinical and Experimental Pathology 8: 107–116.PubMedPubMedCentral
54.
Cui, W.Y., A.Y. Tian, and T. Bai. 2011. Protective effects of propofol on endotoxemia-induced acute kidney injury in rats. Clinical and Experimental Pharmacology & Physiology 38: 747–754.CrossRef
55.
Demiralay, R., N. Gursan, and H. Erdem. 2013. The effects of erdosteine and N-acetylcysteine on apoptotic and antiapoptotic markers in pulmonary epithelial cells in sepsis. The Eurasian Journal of Medicine 45: 167–175.CrossRefPubMedPubMedCentral
56.
Iyoda, M., T. Shibata, M. Kawaguchi, T. Yamaoka, and T. Akizawa. 2009. Preventive and therapeutic effects of imatinib in Wistar-Kyoto rats with anti-glomerular basement membrane glomerulonephritis. Kidney International 75: 1060–1070.CrossRefPubMed
Metadata
Title
A Novel Role of a Chemotherapeutic Agent in a Rat Model of Endotoxemia: Modulation of the STAT-3 Signaling Pathway
Authors
Omnia S. Zaki
Marwa M. Safar
Afaf A. Ain-Shoka
Laila A. Rashed
Publication date
01-02-2018
Publisher
Springer US
Published in
Inflammation / Issue 1/2018
Print ISSN: 0360-3997
Electronic ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-017-0659-5

Other articles of this Issue 1/2018

Inflammation 1/2018 Go to the issue

ORIGINAL ARTICLE

Establishment of S100A8 Transgenic Rats to Understand Innate Property of S100A8 and Its Immunological Role

ORIGINAL ARTICLE

Systemic Inflammatory Response and Multiple Organ Dysfunctions Following Crush Injury: a New Experimental Model in Rabbits

ORIGINAL ARTICLE

Hydrogen-Rich Saline Ameliorates Allergic Rhinitis by Reversing the Imbalance of Th1/Th2 and Up-Regulation of CD4+CD25+Foxp3+Regulatory T Cells, Interleukin-10, and Membrane-Bound Transforming Growth Factor-β in Guinea Pigs

ORIGINAL ARTICLE

Poly(I:C) Priming Exacerbates Cecal Ligation and Puncture-Induced Polymicrobial Sepsis in Mice

Correction

Correction to: Combination Therapy with Pirfenidone plus Prednisolone Ameliorates Paraquat-Induced Pulmonary Fibrosis

ORIGINAL ARTICLE

Fungal β-Glucan Activates the NLRP3 Inflammasome in Human Bronchial Epithelial Cells Through ROS Production
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits